Dr. Mark Agulnik
Claim this profileCity of Hope
Studies Sarcoma
Studies Tumors
23 reported clinical trials
34 drugs studied
About Mark Agulnik
Education:
- Earned an MD from McGill University, Canada, in 1998.
Experience:
- Completed Internal Medicine Residency at Dalhousie University (1999-2001) and a Fellowship in Hematology & Oncology at the University of Illinois Medical Center (2002-2004).
- Over 15 years of service at Northwestern University Feinberg School of Medicine, specializing in sarcomas, head and neck cancer, bone cancer, and soft tissue cancers.
- Joined City of Hope in 2020, contributing significantly as a clinician, educator, and researcher.
- Recognized with multiple awards for his contributions to oncology.
Area of expertise
1Sarcoma
Stage IV
Stage III
p16 positive
2Tumors
Stage IV
Stage III
TSC1 positive
Affiliated Hospitals
Clinical Trials Mark Agulnik is currently running
CDK4/6 Inhibitor
for Liposarcoma
This trial tests SPH4336, a chemotherapy pill, in patients with CDK4-positive liposarcomas. The drug works by blocking an enzyme that cancer cells need to grow, aiming to stop tumor growth.
Recruiting1 award Phase 2
Cemiplimab + Palbociclib
for Liposarcoma
This phase II trial compares the effect of treatment with palbociclib alone to treatment with palbociclib plus cemiplimab for treating patients with dedifferentiated liposarcoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Palbociclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Cemiplimab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. The combination of these two drugs may be more effective in shrinking or stabilizing advanced dedifferentiated liposarcoma compared to palbociclib alone.
Recruiting1 award Phase 2
More about Mark Agulnik
Clinical Trial Related4 years of experience running clinical trials · Led 23 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Mark Agulnik has experience with
- Placebo
- Doxorubicin
- Temozolomide
- Cemiplimab
- BI 907828
- SQ3370
Breakdown of trials Mark Agulnik has run
Sarcoma
Tumors
Soft Tissue Sarcoma
Liposarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mark Agulnik specialize in?
Mark Agulnik focuses on Sarcoma and Tumors. In particular, much of their work with Sarcoma has involved Stage IV patients, or patients who are Stage III.
Is Mark Agulnik currently recruiting for clinical trials?
Yes, Mark Agulnik is currently recruiting for 7 clinical trials in Duarte California. If you're interested in participating, you should apply.
Are there any treatments that Mark Agulnik has studied deeply?
Yes, Mark Agulnik has studied treatments such as Placebo, Doxorubicin, Temozolomide.
What is the best way to schedule an appointment with Mark Agulnik?
Apply for one of the trials that Mark Agulnik is conducting.
What is the office address of Mark Agulnik?
The office of Mark Agulnik is located at: City of Hope, Duarte, California 91010 United States. This is the address for their practice at the City of Hope.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.